Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

PARIS–(BUSINESS WIRE)–Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candid

Go to Source
Author:

Top